Breakthrough in Epilepsy Treatment: Personalized Deep Brain Stimulation Shows 90% Reduction in Seizure Frequency

Researchers at the University of Pittsburgh and UPMC have developed a new treatment for epilepsy patients who don't respond to medication and aren't candidates for surgery. Their approach uses deep brain stimulation (DBS) tailored to each patient's unique brain wiring, published in Nature Communications. Epilepsy affects over 50 million people worldwide, with a third not responding to medication. This new treatment targets the specific area of the thalamus most strongly connected to seizure-prone regions of the cerebral cortex, leading to a dramatic decrease in seizure frequency.

Key Takeaways:

• The research team created detailed maps of seizure activity in 41 patients with drug-resistant epilepsy, using advanced imaging and brain recordings.
• The personalized targeting approach had an average seizure reduction of nearly 90% in patients who received long-term implants.
• Some patients became seizure-free for months at a time, demonstrating the effectiveness of the treatment.
• This study combined multiple techniques - electrical stimulation, imaging, and clinical assessment - within the same patient cohort, a novel approach in epilepsy research.
• The Pittsburgh/UPMC team has previously used thalamus-targeting DBS to restore arm mobility in patients with partial paralysis due to traumatic brain injury and stroke.
• This precise targeting approach could potentially be used to treat other conditions, including psychiatric disorders, such as depression or addiction.

Statistics:

• Over 50 million people worldwide are affected by epilepsy.
• A third of epilepsy patients do not respond to medication.
• The personalized targeting approach had an average seizure reduction of nearly 90% in patients who received long-term implants.
• Some patients became seizure-free for months at a time.
• The study used advanced imaging and brain recordings to create detailed maps of seizure activity in 41 patients.
• The research received financial support from National Institutes of Health grants: 1R01NS122927-01A1 and 1R01NS131428-01A1.

Sources:

• University of Pittsburgh Medical Center (UPMC)
• Nature Communications (peer-reviewed journal)
• National Institutes of Health (grants: 1R01NS122927-01A1 and 1R01NS131428-01A1)
• Rehab Neural Engineering Laboratories (RNEL)
• UPMC Presbyterian